The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma

Primary Outcome Measures:

• Evaluation of presence / absence of CTC on the global survival [ Time Frame: from Baseline in Systolic Blood Pressure at 6 months ] [ Designated as safety issue: No ]
• Value forecasts of the presence / absence of CTC on the global survival estimated by the estimation and the test of meaning at 0 of the immediate relative risk (fate ratio) in a model at proportional risk.

Secondary Outcome Measures:

• Value forecasts of the number of CTC on the global survival estimated by the risk [ Time Frame: from Baseline in Systolic Blood Pressure at 6 months ] [ Designated as safety issue: No ]
• Value forecasts of the number of CTC on the global survival estimated by the immediate relative risk Value forecasts of the presence / absence and the number of CTC on the survival without second offense(recurrence) or metastasis estimated by the immediate relative risk

Eligibility Criteria

Inclusion Criteria:

For the patients:

• Age > 18 years
• Patient having been operated for a strong suspicion of pleural malignant tumoral lesion corresponding to a primitive pleural mesothelioma
• Signed patient consent

For the control subjects:

• Age > 18 years
• Unhurt of any malignant or mild tumoral pathology or patients that must benefit from a surgical procedure for a benign lesion in other organ than the pleura or a pulmonary non tumoral lesion
• Signed patient consent

Exclusion Criteria:

• Patient with histories of cancer or the other synchronous cancer
• Patient with additives treatments
• Patient according to treatments additives other than protocols codified (in particular, platinum navelbine or gemcitabine platinum) for stages II
• HIV, hepatitis B or C infections
• Pregnant women